F or the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring 'razor ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...